Carmell Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Kendra Bracken-Ferguson

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	17.8yrs
Board average tenure	less than a year

Recent management updates

Recent updates

Carmell (NASDAQ:CTCX) Is Making Moderate Use Of Debt

Mar 24

CEO

Kendra Bracken-Ferguson

less than a year

Tenure

Ms. Kendra Bracken-Ferguson is Member of National Advisory Board of Blushington LLC from October 2024. Ms. Bracken-Ferguson is Chief Executive Officer at Carmell Corporation since July 30, 2024. She served...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Rajiv Shukla	Executive Chairman	1.3yrs	US$1.20m	15.92% $ 817.2k
Bryan Cassaday	Chief Financial Officer	1.4yrs	US$476.21k	0.020% $ 1.0k
Kendra Bracken-Ferguson	Chief Executive Officer	less than a year	no data	no data
Phil Campbell	Founder and Chief Scientific Officer	17.8yrs	no data	no data
Lee Weiss	Founder	17.8yrs	no data	no data
James Burgess	Founder	17.8yrs	no data	no data

17.8yrs

Average Tenure

Experienced Management: CTCX's management team is seasoned and experienced (17.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Rajiv Shukla	Executive Chairman	1.3yrs	US$1.20m	15.92% $ 817.2k
Patrick Sturgeon	Independent Director	1.3yrs	US$180.39k	0.46% $ 23.8k
Richard Upton	Independent Director	13.6yrs	US$25.00k	0.072% $ 3.7k
Kathryn Gregory	Independent Director	3.8yrs	US$25.00k	0.032% $ 1.7k
M. Calobrace	Member of Scientific Advisory Board	less than a year	no data	no data
Gregory Buford	Member of Scientific Advisory Board	less than a year	no data	no data
Scott Frisch	Independent Director	less than a year	US$167.89k	0.026% $ 1.3k
Jason Bloom	Member of Scientific Advisory Board	less than a year	no data	no data
Gilles Spenlehauer	Independent Director	less than a year	US$167.89k	0.026% $ 1.3k
Adam Rubinstein	Member of Scientific Advisory Board	less than a year	no data	no data
Sean Kelishadi	Member of Scientific Advisory Board	less than a year	no data	no data

1.0yrs

Average Tenure

60yo

Average Age

Experienced Board: CTCX's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.

Carmell Management

Management criteria checks 1/4

Key information

Recent management updates

Carmell Corporation Appoints Kendra Bracken-Ferguson as Chief Executive Officer Effective July 30, 2024

Carmell Corporation, Annual General Meeting, Jul 12, 2024

High number of new and inexperienced directors

Carmell Corp Announces Appointment of Dr. Jason D. Bloom to Scientific Advisory Board

Carmell Corporation Announces Addition of Two Independent Directors

Carmell Corporation Announces Board Changes

Recent updates

Carmell Corporation has withdrawn its Follow-on Equity Offering.

Carmell Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2)

Carmell Receives Letter from Nasdaq Regarding Non-Compliance with the Market Value of Listed Securities Requirement

Carmell Receives Letter from Nasdaq Regarding Non-Compliance with the Market Value of Listed Securities Requirement

New major risk - Financial position

Carmell Corporation Appoints Kendra Bracken-Ferguson as Chief Executive Officer Effective July 30, 2024

Carmell Corporation, Annual General Meeting, Jul 12, 2024

New major risk - Negative shareholders equity

Carmell Corporation announced that it has received $3 million in funding

Carmell Corporation announced that it expects to receive $3 million in funding

New major risk - Revenue size

Carmell (NASDAQ:CTCX) Is Making Moderate Use Of Debt

An undisclosed buyer entered into a a definitive agreement to acquire Axolotl Biologix, Inc. from Carmell Corporation (NasdaqCM:CTCX) ).

Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024

High number of new and inexperienced directors

Carmell Corp Announces Appointment of Dr. Jason D. Bloom to Scientific Advisory Board

Carmell Corporation Announces Addition of Two Independent Directors

Carmell Corporation Announces Board Changes

Carmell Therapeutics Corporation (NasdaqCM:CTCX) completed the acquisition of Axolotl Biologix, Inc.

Carmell Therapeutics Corporation (NasdaqCM:CTCX) entered into a definitive agreement to acquire Axolotl Biologix, Inc.

Less than half of directors are independent

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age